论文部分内容阅读
在肺癌的治疗中放射治疗占有重要地位,其适应证宽,禁忌证少,症状缓解率高(75～80%),危险牲小。放疗后的五年生存率一般仅2～10%,这与适应证宽显然有一定关系。有人将适应证收紧到限于能手术的肺癌,五年生存率就提高到22.5%,若再限于无淋巴结转移者,则更提高到41%。各种病理类型中以肺鳞癌的放疗后生存率最高。小细胞癌最低,肺癌的变动范围较大。肺癌根治性放疗时必须照射原发灶及第一、二站淋巴结(纵隔淋巴结的转移率高达60%)。要照射这样
Radiotherapy plays an important role in the treatment of lung cancer, with wide indications, fewer contraindications, and high symptom remission rates (75 to 80%). The five-year survival rate after radiotherapy is generally only 2 to 10%, which obviously has a certain relationship with the indication card width. Some people have tightened their indications until they are limited to lung cancer that can be operated on. The five-year survival rate increases to 22.5%, and if it is no longer limited to those who do not have lymph node metastasis, it increases to 41%. The survival rate after radiotherapy for lung squamous cell carcinoma was highest in all pathological types. Small cell carcinoma is the lowest, and the range of lung cancer changes. Radical lung cancer must be irradiated with primary tumors and lymph nodes at the first and second stations (the metastatic rate of mediastinal lymph nodes is as high as 60%). To shine this way